Dr. Molony’s science background and industry experience in both drug discovery and business development will be integral to the Institute’s business development team. Dr. Molony received both her B.S. (Physics) and Ph.D. (Anatomy/Cell Biology) degrees from Duke Univer¬sity, and completed postdoctoral studies at the University of North Carolina. She completed course work for the Certificate in Financial Management at the University of California, San Diego. As a business development consultant, she has worked with global firms including EBD Group, ProPharma Partners, and Recombinant Capital Prior to joining Sanford-Burnham, Dr. Molony was President, CEO & Director of Transgeneron Therapeutics, Inc. in Gainesville, Florida. She is the founder of RiverWood BioConsulting through which she served as Business Development Principal for Sunesis Pharmaceuticals, Inc., SVP Business Development for Nanotherapeutics, Inc. and Interim CEO of St Charles Pharmaceuticals.
“Dr. Molony has a track record that demonstrates her strong business acumen, including many successful licensing transactions and experience with company formation,” said Paul Laikind, Ph.D., Senior Vice President, Business Development and Chief Business Officer. “Her entrepreneurial spirit, and well-developed industry relationships will help us to maximize the impact of Institute research.” Dr. Laikind leads Sanford-Burnham’s business development activities on an international basis to strategically evaluate and leverage the Institute’s research.
Dr. Molony will also serve as a spokesperson and Institute representative for Florida’s biotech community. “We are thrilled that Dr. Molony will be joining Sanford-Burnham and our Lake Nona Medical City partners as we create a vibrant cluster of life sciences innovation and commercialization in Central Florida,” said Thad Seymour, Vice President and General Manager, Health and Life Science Investments, Lake Nona Holdings.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute (Sanford-Burnham) is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top independent research institutions nationally for NIH grant funding and among the top organizations worldwide for its research impact. From 1999–2009, Sanford-Burnham ranked #1 worldwide among all types of organizations in the fields of biology and biochemistry for the impact of its research publications, defined by citations per publication, according to the Institute for Scientific Information. According to government statistics, Sanford-Burnham ranks #2 nationally among all organizations in capital efficiency of generating patents, defined by number of patents issued per grant dollars awarded.
Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a nonprofit public benefit corporation. For more information visit www.sanfordburnham.org.
